More knowledge is usually
considered a good thing. And in the past 20 years there has been an exponential
increase in the amount of scientific and experiential knowledge that underpins
the biopharmaceutical industry.
But knowledge has its
downsides. According to biotech veterans, the industry's greater knowledge has
made it harder to start and build new companies in two key ways: Both public
and private investors are far more savvy than they were two decades ago, while
most of the "easy" diseases and indications have been picked off.